2024
Characterizing the progression of subclinical cardiac amyloidosis through artificial intelligence applied to electrocardiographic images and echocardiograms
Oikonomou E, Sangha V, Coppi A, Krumholz H, Miller E, Khera R. Characterizing the progression of subclinical cardiac amyloidosis through artificial intelligence applied to electrocardiographic images and echocardiograms. European Heart Journal 2024, 45: ehae666.2089. DOI: 10.1093/eurheartj/ehae666.2089.Peer-Reviewed Original ResearchDiagnosis of ATTR-CMATTR-CMBone scintigraphy scansClinical diagnosisTransthyretin amyloid cardiomyopathyMonths of diagnosisSex-matched controlsElectrocardiographic (ECGIndolent courseCardiac amyloidosisScintigraphy scanAmyloid cardiomyopathyEchocardiographic studiesAI-ECGEchocardiogramEventual diagnosisDetect longitudinal changesConfirmatory testDiagnosisClinical diseasePercentage of individualsLongitudinal changesECGMedianMonths
2017
Heterogeneity in Early Responses in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial)
Dhruva SS, Huang C, Spatz ES, Coppi AC, Warner F, Li SX, Lin H, Xu X, Furberg CD, Davis BR, Pressel SL, Coifman RR, Krumholz HM. Heterogeneity in Early Responses in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial). Hypertension 2017, 70: 94-102. PMID: 28559399, DOI: 10.1161/hypertensionaha.117.09221.Peer-Reviewed Original ResearchConceptsAntihypertensive therapySystolic blood pressure responseAdverse cardiovascular eventsFavorable initial responseBlood pressure responseHigher hazard ratioCardiovascular eventsCardiovascular outcomesHazard ratioMultivariable adjustmentHeart failureAverage SBPRandomized trialsOdds ratioCardiovascular diseaseSBPStudy participantsRespondersMonthsPressure responseImmediate respondersALLHATEarly responseInitial responseSuperior discrimination